BUSINESS
MFs go fishing for value in stock market's most hated pocket
Majority of the analysts on Dalal Street have a ‘buy’ call on these stocks, with a potential upside of 26-64 percent over the next 12 months.
BUSINESS
IT stocks head for worst year since 2008 as growth winter sets in
The drawdown this year also marks an end to a five-year long streak of positive returns from information technology stock benchmark
BUSINESS
RBI Monetary Policy | Just like the Fed, an RBI pivot remains elusive for Dalal Street
The MPC has delivered on the expectations as far as the quantum of the rate hike is concerned as it raised the repo rate to 6.25 percent from 5.9 percent earlier but the pivot on future rate hikes remained elusive
BUSINESS
Foreign investors pull out record $18 billion from 8th largest stock market in 2022
World-beating returns was not enough for foreign investors who pulled out money in large amounts thanks to rising global interest rates and a weakening local currency
BUSINESS
Pivot Powell to China's comeback: 4 global themes that will define investing in 2023
Equities may see a rout while bonds may emerge bigger in the "year of the yield", predict global investment banks
BUSINESS
Why is ICICI Prudential MF doubling down on battered Nykaa?
The asset manager has snapped up 11.1 million shares in Nykaa’s parent since November 10. That’s roughly 16 percent of the shares sold since the end of the lock-in period for pre-IPO investors.
BUSINESS
Fear index for stock market hits 14-month low as investor confidence builds up
The volatility gauge has fallen 83 percent from the record high of 86.63 touched on March 24, 2020, which also marked the bottom for the COVID-19 linked crash in the global stock markets.
BUSINESS
List of FIIs seeking an out from NSE continues to grow longer
The latest is Morgan Stanley, which is seeking to sell 7-10 lakh shares of NSE through the auction process with a base price of Rs 2,750-2,800. This is at a steep discount of 9-15% over the last available unofficial quote. Also, the number of foreign direct and portfolio investors exiting the exchange itself is increasing.
BUSINESS
Buccaneering traders bet Nifty rally has more legs to run on
In 2022, Indian stocks have outperformed amid continued buying from domestic institutional and retail investors, given the resilient outlook for the economy
BUSINESS
Q2 review | IT earnings better than feared but road ahead bumpy
The commentary from the management of most major IT companies betrayed a level of uncertainty in their assessment of the demand environment, something not seen in previous earnings calls
BUSINESS
Diagnostic giant warns cash-burning startups they have got it all wrong
Backed by deep-pocketed venture capitalists and private equity funds, health technology startups have sprouted in the diagnostics sector over the past five years, hoping to disrupt the existing status quo through low-cost testing procedures
BUSINESS
Worries over UPL's bulging debt fail to enthuse investors despite big-bang private equity placement
The restructuring exercise has given UPL net proceeds of $259 million, which brokerage firm Prabhudas Lilladher believes will be used towards paring down its debt levels going ahead.
BUSINESS
Exclusive | US FDA finds procedural issues at Lupin’s Nagpur injectables plant
Lupin, in an exchange filing on October 30 acknowledging the receipt of the form 482, said that the inspection pertained to pre-approval of its unit two.
BUSINESS
Cipla Q2 preview | Consolidated net profit likely to rise 9% YoY
In the year-ago quarter, Cipla benefitted from the surge in sales of COVID-19-related drugs
BUSINESS
How long will US Fed keep raising the interest rate?
Economic data over the past few months have showed little sign of stress in the US economy
BUSINESS
Sun Pharma’s specialty drugs bet is beginning to pay off
Sun Pharmaceutical’s foray into specialty drugs was in some ways driven by an existential threat posed by rising competition to its generic drug business in the US. In the September quarter, it reported sales of $200 million from specialty drugs in the US, up 27.5 percent YoY
BUSINESS
Nykaa’s new CTO aims to embrace crypto, metaverse to boost user engagement
The former Amazon executive said that in the coming weeks, he will interact with Nykaa's stakeholders to develop more efficient and effective platforms for its customers.
BUSINESS
Preview | UPL to see strong growth in Q2 earnings driven by India operations
The company will report its quarterly earnings on November 1, just days after it announced a massive restructuring of its business to unlock value.
BUSINESS
Q2 Preview | Sun Pharma consolidated net may drop 4% on high R&D costs
Sun Pharmaceutical’s consolidated revenues, however, are expected to rise 13.2 percent on a year-on-year basis aided by growth in US specialty products and domestic formulations portfolio
BUSINESS
Inflation fight likely to trigger Rs 27,000 crore in losses for PSU refiners in Q2
The cumulative net loss of OMCs in the September quarter will be the highest since the June quarter of 2012-13 when they reported a combined loss of Rs 40,536 crore
BUSINESS
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz
Dr Reddy’s North American operations will set the tone for the September quarter performance, as likely price erosion will trigger a decline in sales on a year-on-year basis
IPO
PharmEasy’s annus horribilis may get worse before it gets better
The funding winter confronting startups this year owing to surging global interest rates, the capitulation of technology stocks amid fears of a recession in the West and increasing investor dislike for loss-making, cash-burning companies has hit the online pharmacy giant hard.
BUSINESS
Earnings, global factors key to a good show this Samvat
As investors look forward to the new samvat, many of the same issues will continue to plague global markets including surging inflation, a slowing global economy and heightened geopolitical uncertainties
BUSINESS
RIL gains as co to demerge, list Jio Financial Services
On October 21, RIL announced that shareholders will get one share of Jio Financial Services for every one share held in the company by them.
